干扰素、病毒唑抗呼吸道合胞病毒的体外观察

目的 观察重组人干扰素、病毒唑单独及联合体外抗呼吸道合胞病毒(RSV) 的效果。方法 细胞病变抑制法, 即测定药物单独及联合应用对RSV 所致细胞病变的抑制作用。结果 干扰素浓度≥5 IU·ml^-1或病毒唑浓度≥24 μg·ml^-1时, 随着药物浓度的增加、抑制细胞病变的作用也增强, 直至不出现细胞病变(P <0.01); 两药在低于各自的有效浓度时合用, 即干扰素1 IU·ml^-1、病毒唑12 μg·ml^-1, 仍具有明显的抑制细胞病变作用(P ≤0.01)。结论 重组人干扰素及病毒唑体外均有抗RSV 作用, 联合应用时作用更甚。

Observing study on virazole and interferon resisting respiratory synthesis virus in vitro

Aim To observe the effect of recombinant human interferon and verazole used alone or in combination in resisting respiratory synthesis virus (RSV) in vitro. Methods RSV strains were proliferated with Hela cells in Eagles solution on a 96-hole plate. The recombinant human interferon and virazole were diluted to different concentrations and were separately added in the dose of 100 μl to each hole of the plate. After 48 hours cultured, the concentrations of the drugs for inhibiting cytopathogenic effect (CPE) of RSV were determined. Results When the concentration of interferon was ≥5 U·ml^-1 and virazlole ≥ 24 μg·ml^-1, respectively, the effect of the two drugs on inhibiting the CPE of RSV was remarkable and was improved with their concentration increasing. When the concentrations of the two drugs were lower than that of their effect respectively, their united use also had obvious effect in resisting the virus. In addition, the different using methods of interferon have also different results. Conclusion Both recombinant human interferon and virazole are effective in inhibiting RSV in vitro and will bring about better effect when used in combination.